A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Trial Profile

A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Alpelisib (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Jul 2016 Planned End Date changed from 1 Sep 2023 to 1 Aug 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top